The content on this site is intended for healthcare professionals only
Dr Gnant talks to ecancertv at ESMO 2016 about the results of the MONALEESA-2 and PALOMA-2 trials, which confirm, he says, that the addition of cell cycle inhibitors (specifically, CDK4/6) can be of great benefit to patients with metastatic breast cancer.
He discusses the results of both trials with particular regards to toxicity.
MONALEESA-2 was discussed further by Dr Gabriel Hortobagyi here, and featured in the ecancer symposium on CDK4/6 inhibitors.
Supported by a grant from Pfizer Inc.
Targeted therapies associated with increased risk for and incidence of thrombosis in the treatment of breast cancer
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Hormonal receptor positive breast cancer adjuvant and metastatic indications
OncoAlert round up July 28th to August 3rd, 2023
Updates on triple-negative breast cancer and immunotherapy
Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC
LUMINANCE: Results support use of durvalumab and platinum-etoposide for extensive stage SCLC
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer
Management of HER2 positive metastatic breast cancer treatment algorithm
